- Home
- BRW vs ACRS Comparison
BRW vs ACRS Comparison
Compare BRW & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | ACRS |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 314.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRW | ACRS |
|---|---|---|
| Price | $7.02 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 222.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 15.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.15 | $1.05 |
| 52 Week High | $8.30 | $3.48 |
Technical Indicators
Market Signals| Indicator | BRW | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 42.35 |
| Support Level | $6.95 | $2.49 |
| Resistance Level | $7.04 | $3.04 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 49.97 | 24.68 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.